Weight Loss & Metabolism
The incretin-based peptide therapies represent one of the most significant pharmaceutical developments of the past decade. GLP-1 receptor agonists like semaglutide, and dual GIP/GLP-1 agonists like tirzepatide, have demonstrated unprecedented efficacy in clinical trials for both type 2 diabetes and chronic weight management.
Unlike most peptide categories on this site, the weight loss peptides listed here have strong clinical evidence from large randomized controlled trials and are FDA-approved for human use. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have been studied in clinical programs enrolling tens of thousands of participants.
These peptides work through incretin receptor pathways, enhancing insulin secretion, suppressing glucagon, reducing appetite through central nervous system mechanisms, and slowing gastric emptying.
| Peptide | Evidence | Status |
|---|---|---|
| Amylin (IAPP) | Strong | FDA Approved |
| Cagrilintide (AM833) | Strong | phase-3 |
| Mazdutide (IBI362 / LY3305677) | Strong | FDA Approved |
| Pramlintide (Symlin) | Strong | FDA Approved |
| Retatrutide | Strong | phase-3 |
| Semaglutide | Strong | FDA Approved |
| Setmelanotide | Strong | FDA Approved |
| Survodutide (BI 456906) | Strong | phase-3 |
| Tirzepatide | Strong | FDA Approved |
| Danuglipron | Moderate | discontinued |
| Pemvidutide (ALT-801) | Moderate | Phase II |
| Adipotide (FTPP) | Preliminary | Phase I |
| AOD-9604 (Anti-Obesity Drug 9604) | Preliminary | Phase II |
| HGH Fragment 176-191 | Preliminary | Preclinical |
| 5-Amino-1MQ | Preclinical | Preclinical |
| GIP (Glucose-dependent Insulinotropic Polypeptide) | Insufficient | investigational-endogenous-hormone |
| GLP-1 (Glucagon-Like Peptide 1) | Insufficient | endogenous-hormone |